A review of methods for futility stopping based on conditional power.
نویسنده
چکیده
Conditional power (CP) is the probability that the final study result will be statistically significant, given the data observed thus far and a specific assumption about the pattern of the data to be observed in the remainder of the study, such as assuming the original design effect, or the effect estimated from the current data, or under the null hypothesis. In many clinical trials, a CP computation at a pre-specified point in the study, such as mid-way, is used as the basis for early termination for futility when there is little evidence of a beneficial effect. Brownian motion can be used to describe the distribution of the interim Z-test value, the corresponding B-value, and the CP values under a specific assumption about the future data. A stopping boundary on the CP value specifies an equivalent boundary on the B-value from which the probability of stopping for futility can then be computed based on the planned study design (sample size and duration) and the assumed true effect size. This yields expressions for the total type I and II error probabilities. As the probability of stopping increases, the probability of a type I error alpha decreases from the nominal desired level (e.g. 0.05) while the probability of a type II error beta increases from the level specified in the study design. Thus a stopping boundary on the B-value can be determined such that the inflation in type II error probability is controlled at a desired level. An iterative procedure is also described that determines a stopping boundary on the B-value and a final test critical Z-value with specified type I and II error probabilities. The implementation in conjunction with a group sequential analysis for effectiveness is also described.
منابع مشابه
Futility stopping in clinical trials
Early stopping due to futility, also referred to as a go/nogo decision, during interim analysis has become an important feature of clinical trial designs. Current methods for futility stopping in literature are mostly based on conditional power or predictive power in conjunction with the theory of stochastic curtailment or group sequential design. They have certain drawbacks that have been note...
متن کاملAn Adaptive Futility Monitoring Method with Time-Varying Conditional Power Boundary
For a long-term randomized clinical trial, it has become a well-accepted practice to include interim analyses in trial protocols. In addition to design an efficacy monitoring plan, investigators often develop a futility monitoring plan as well to prevent continuing a trial that has little chance to demonstrate treatment efficacy. Conditional power is the probability that the final analysis will...
متن کاملAn investigation of the impact of futility analysis in publicly funded trials
BACKGROUND Publicly funded trials regularly fail to recruit their target sample size or find a significant positive result. Adaptive clinical trials which may partly mediate against the problems are not often applied. In this paper we investigate the potential of a form of adaption in a clinical trial - a futility analysis - to see if it has potential to improve publicly funded trials. METHOD...
متن کاملFutility in Complementary and Alternative Medicine: A Critical Review from an Ethical Perspective
Several definitions for medical futility has been proposed in the literature. Medical futility is defined as the condition in which an intervention, either for diagnosis, prevention, treatment, rehabilitation or other medical goals, has no benefit for the individual patient. This critical review aimed to increase the understanding of physicians and other healthcare providers on the issue of fut...
متن کاملChallenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience.
BACKGROUND AND PURPOSE Interventional Management of Stroke (IMS) III is a randomized, parallel arm trial comparing the approach of intravenous tissue-type plasminogen activator followed by endovascular treatment with intravenous tissue-type plasminogen activator alone in patients with acute ischemic stroke presenting <3 hours of symptom onset. The trial intended to enroll 900 subjects to ensure...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Statistics in medicine
دوره 24 18 شماره
صفحات -
تاریخ انتشار 2005